The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

Author(s): Allan Iversen, Soren Galatius, Jan S. Jensen

Journal Name: Current Cardiology Reviews

Volume 4 , Issue 4 , 2008

Become EABM
Become Reviewer
Call for Editor


The use of the glycoprotein (GP) IIb/IIIa receptor antagonist Abciximab has over the years become an important part of the anticoagulant regimen in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Abciximab is a potent inhibitor of platelet aggregation and thrombus formation, but other mechanisms, such as suppression of the inflammatory pathways, have also been proposed to contribute to the benefits of Abciximab. The optimal route of administration, i.e. intravenous versus intracoronary, of the first dose has been questioned, but only tested in small, non-randomised and retrospective studies or studies with short follow-up. No definite conclusion can be made based on these studies In this review we present the current knowledge published about the intracoronary administration of Abciximab including the mechanisms behind the potential beneficial effects, and the safety. The emphasis will be on clinical trials rather than on studies on the pharmacological mechanisms, as the latter have been reviewed thoroughly elsewhere. Our conclusion from this present review is that randomized trials of intracoronary versus intravenous bolus of Abciximab are needed.

Keywords: Abciximab, coronary heart disease, glycoprotein IIb/IIIa, intracoronary, intravenous, percutaneous coronary intervention

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Published on: 01 March, 2012
Page: [293 - 299]
Pages: 7
DOI: 10.2174/157340308786349480
Price: $65

Article Metrics

PDF: 3